Alternative transfuziji krvi i financijska isplativost
Onkologija
Should intravenous iron be the standard of care in oncology? (otvara se novi prozor)
Izvor: J Clin Oncol 2008;26(10):1579-81.
Indeks: PubMed 18375888
DOI: 10.1200/JCO.2007.15.4609
https://www.ncbi.nlm.nih.gov/pubmed/18375888 (otvara se novi prozor)
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. (otvara se novi prozor)
Izvor: Acta Oncol 2008;47(6):1009-17.
Indeks: PubMed 18770060
DOI: 10.1080/02841860701744498
https://www.ncbi.nlm.nih.gov/pubmed/18770060 (otvara se novi prozor)
Cost of outpatient blood transfusion in cancer patients. (otvara se novi prozor)
Izvor: J Clin Oncol 2000;18(14):2755-61.
Indeks: PubMed 10894876
DOI: 10.1200/JCO.2000.18.14.2755
https://www.ncbi.nlm.nih.gov/pubmed/10894876 (otvara se novi prozor)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (otvara se novi prozor)
Izvor: Transfusion 2015;55(12):2807-15.
Indeks: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (otvara se novi prozor)